CancerDrs

Lung Cancer clinical trials in Florida

86 actively recruiting lung cancer trials at 69 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full lung cancer transparency page →

Phase 3 Recruiting NIH

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04267848
Sites in Florida:
  • Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
  • Holy Cross Hospital — Fort Lauderdale, Florida
  • Regional Cancer Center-Lee Memorial Health System — Fort Myers, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Baptist MD Anderson Cancer Center — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…

Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in Florida:
  • Bay Pines VA Healthcare System — Bay Pines, Florida
  • Morton Plant Hospital — Clearwater, Florida
  • Halifax Health Medical Center-Centers for Oncology — Daytona Beach, Florida
  • Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
  • Mayo Clinic in Florida — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Florida:
  • GenesisCare USA — Aventura, Florida
  • Bay Pines Veterans Affairs Healthcare System — Bay Pines, Florida
  • Local Institution - 007-922-A — Bonita Springs, Florida
  • Local Institution - 007-922-D — Bradenton, Florida
  • Local Institution - 007-922-E — Cape Coral, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…

Sponsor: Pfizer
NCT ID: NCT07222566
Sites in Florida:
  • Florida Cancer Specialists — Bonita Springs, Florida
  • Florida Cancer Specialists — Bradenton, Florida
  • Florida Cancer Specialists — Cape Coral, Florida
  • Florida Cancer Specialists — Clearwater, Florida
  • BRCR Global- Coral Springs — Coral Springs, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change …

Sponsor: Eli Lilly and Company
NCT ID: NCT06119581
Sites in Florida:
  • Millennium Oncology Research Clinic — Hollywood, Florida
  • University of Florida - Jacksonville — Jacksonville, Florida
  • Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
  • Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala — Ocala, Florida
  • Orlando Health Cancer Institute — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Sponsor: Summit Therapeutics
NCT ID: NCT06767514
Sites in Florida:
  • Clinical Study Site — Fort Lauderdale, Florida
  • Clinical Study Site — Hialeah, Florida
  • Clinical Study Site — Jacksonville, Florida
  • Clinical Study Site — Miami, Florida
  • Clinical Study Site — North Venice, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if ol…

Sponsor: Eli Lilly and Company
NCT ID: NCT06890598
Sites in Florida:
  • Boca Raton Regional Hospital — Boca Raton, Florida
  • Florida Cancer Specialists - South — Fort Myers, Florida
  • University of Florida - Jacksonville — Jacksonville, Florida
  • Miami Cancer Institute at Baptist Health, Inc. — Miami, Florida
  • Ocala Oncology Center PL DBA Florida Cancer Affiliates - Ocala — Ocala, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary en…

Sponsor: Summit Therapeutics
NCT ID: NCT05899608
Sites in Florida:
  • Florida Cancer Specialists & Research Institute (FCS)-East — Fort Myers, Florida
  • BioResearch Partner- Hialeah Hospital — Hialeah, Florida
  • Mayo Clinic — Jacksonville, Florida
  • Cancer Specialists of North Florida — Jacksonville, Florida
  • Ocala Oncology — Ocala, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…

Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in Florida:
  • Local Institution - 0694 — Clearwater, Florida
  • Cancer Specialists of North Florida — Jacksonville, Florida
  • Local Institution - 0696 — Miami, Florida
  • Local Institution - 0680 — Ocala, Florida
  • Mid Florida Hematology and Oncology Center — Orange City, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in Florida:
  • The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156) — Fort Lauderdale, Florida
  • Miami Cancer Institute at Baptist Health, Inc. ( Site 0214) — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Florida:
  • University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami, Florida
  • Memorial Hospital West — Pembroke Pines, Florida
  • Florida Cancer Specialists - North — St. Petersburg, Florida
  • Local Institution - 0477 — Tamarac, Florida
  • Florida Cancer Specialists - East — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Florida:
  • Helios Clinical Research - Fort Lauderdale — Fort Lauderdale, Florida
  • Mayo Clinic in Florida — Jacksonville, Florida
  • Local Institution - 0430 — St. Petersburg, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Florida:
  • University of Florida (Adults and Pediatrics) — Gainesville, Florida
  • University of Miami/Jackson Memorial Hospital (Adults only) — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Sponsor: AstraZeneca
NCT ID: NCT06868277
Sites in Florida:
  • Research Site — Bay Pines, Florida
  • Research Site — Clearwater, Florida
  • Research Site — St. Petersburg, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).

Sponsor: AstraZeneca
NCT ID: NCT06417814
Sites in Florida:
  • Research Site — Gainesville, Florida
  • Research Site — Jacksonville, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation thera…

Sponsor: Shanghai Junshi Bioscience Co., Ltd.
NCT ID: NCT06095583
Sites in Florida:
  • Florida Cancer Specialists Pan Handle — Fort Myers, Florida
  • Florida Cancer Specialists South — Fort Myers, Florida
  • USA029 University of Miami Sylvester Comprehensive Cancer Center 1550 NW 10th Avenue 33173 Miami FL Ikpeazu Chukwuemeka N — Miami, Florida
  • Mid-Florida Hematology Oncology — Orange City, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has …

Sponsor: Pfizer
NCT ID: NCT07226999
Sites in Florida:
  • BRCR Coral Springs — Coral Springs, Florida
  • Mid Florida Hematology and Oncology Center — Orange City, Florida
  • BRCR Global - Tamarac — Tamarac, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in…

Sponsor: Nuvation Bio Inc.
NCT ID: NCT07154706
Sites in Florida:
  • Advent Health — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging …

Sponsor: Vergent Bioscience, Inc.
NCT ID: NCT07499674
Sites in Florida:
  • Orlando Health Cancer Center — Orlando, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers

Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of PRV111 in patients with Carcinoma in Sit…

Sponsor: Privo Technologies
NCT ID: NCT05893888
Sites in Florida:
  • Miami Cancer Institute — Miami, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06031688
Sites in Florida:
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated (EGFRm) non-smal…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06667076
Sites in Florida:
  • Baptist Lynn Cancer Institute — Boca Raton, Florida
  • The Oncology Institute of Hope and Innovation 1 — Fort Lauderdale, Florida
  • Florida Cancer Specialists — Fort Myers, Florida
  • Univ of Florida — Gainesville, Florida
  • Memorial Regional Hospital — Hollywood, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT04614103
Sites in Florida:
  • University of Florida Health Cancer Center — Gainesville, Florida
  • Sylvester Comprehensive Cancer Center — Miami, Florida
  • AdventHealth Cancer Institute — Orlando, Florida
  • H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
View on ClinicalTrials.gov →

Showing 25 of 86 trials with sites in Florida. See all lung cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15